Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
American Journal of Clinical Pathology|December 1, 1988
Comparative analysis of glycosylated hemoglobins by ion-exchange column chromatography and high-performance liquid chromatography in patients with hemoglobinopathiesN S Torké, P S Mehta, R M Vohra, et al.
Science (New York, N.Y.)|February 23, 1996
The p21(RAS) farnesyltransferase alpha subunit in TGF-beta and activin signalingT Wang, P D Danielson, B Y Li, et al.
American Journal of Hematology|February 19, 2000
Activated recombinant human coagulation factor VII (rFVIIa) therapy for abdominal bleeding in patients with inhibitory antibodies to factor VIIIH A Liebman, J Chediak, K I Fink, et al.
Genes & Development|March 15, 1994
The v-abl tyrosine kinase negatively regulates NF-kappa B/Rel factors and blocks kappa gene transcription in pre-B lymphocytesC A Klug, S J Gerety, P C Shah, et al.
The American Journal of Physiology|November 14, 1997
Intestinal ischemia and reperfusion injury in transgenic mice overexpressing copper-zinc superoxide dismutaseD R Deshmukh, O Mirochnitchenko, V S Ghole, et al.
Cell|August 9, 1996
The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptorsT Wang, B Y Li, P D Danielson, et al.
Endocrinology|January 1, 1996
Developmental expression of a candidate müllerian inhibiting substance type II receptorJ Teixeira, W W He, P C Shah, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 28, 2000
Human coagulation factor FVIIa (recombinant) in the management of limb-threatening bleeds unresponsive to alternative therapies: results from the NovoSeven emergency-use programme in patients with severe haemophilia or with acquired inhibitorsS Arkin, F Blei, J Fetten, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 1999
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MISP T Masiakos, D T MacLaughlin, S Maheswaran, et al.
Pageof 4